Metropolis Healthcare Ltd
NSE:METROPOLIS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Metropolis Healthcare Ltd
Other Long-Term Assets
Metropolis Healthcare Ltd
Other Long-Term Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Long-Term Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Metropolis Healthcare Ltd
NSE:METROPOLIS
|
Other Long-Term Assets
₹132m
|
CAGR 3-Years
32%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
|
|
Dr Agarwal's Eye Hospital Ltd
BSE:526783
|
Other Long-Term Assets
₹210.8m
|
CAGR 3-Years
9%
|
CAGR 5-Years
10%
|
CAGR 10-Years
16%
|
|
|
Thyrocare Technologies Ltd
NSE:THYROCARE
|
Other Long-Term Assets
₹144.9m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
|
|
Dr. Lal PathLabs Ltd
NSE:LALPATHLAB
|
Other Long-Term Assets
₹913m
|
CAGR 3-Years
23%
|
CAGR 5-Years
26%
|
CAGR 10-Years
11%
|
|
|
Vijaya Diagnostic Centre Ltd
NSE:VIJAYA
|
Other Long-Term Assets
₹222.2m
|
CAGR 3-Years
24%
|
CAGR 5-Years
19%
|
CAGR 10-Years
N/A
|
|
|
Krsnaa Diagnostics Ltd
NSE:KRSNAA
|
Other Long-Term Assets
₹424.5m
|
CAGR 3-Years
90%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
N/A
|
|
Metropolis Healthcare Ltd
Glance View
Metropolis Healthcare Ltd., a pioneer in the diagnostics industry, embarked on its journey in 1980 under the visionary leadership of Dr. Sushil Kanubhai Shah. This Mumbai-based company quickly established itself as a trusted name, offering a comprehensive range of diagnostic services, including pathology tests, radiology, and wellness solutions. The heart of its operations lies in its expansive network of laboratories and collection centers strategically distributed across India and several international locations. By leveraging state-of-the-art technology and maintaining rigorous quality standards, Metropolis has positioned itself as a forerunner in providing precise and reliable medical test results. This was especially crucial as the demand for accurate healthcare diagnostics surged, driven by an increasingly health-conscious population. Metropolis generates its revenue primarily through fees charged for its broad spectrum of diagnostic tests that cater to a variety of health needs, from routine screenings to specialized, high-complexity tests. Its business model capitalizes on partnerships with healthcare providers, hospitals, and corporations, offering customized health packages and diagnostic solutions that ensure a steady flow of clientele. By integrating advanced testing technologies and continuously expanding its service portfolio, the company taps into diverse revenue streams, which include corporate wellness programs and home health services. This diversified approach not only enhances its financial stability but also solidifies its reputation as a go-to healthcare partner for individuals, corporate clients, and healthcare institutions alike.
See Also
What is Metropolis Healthcare Ltd's Other Long-Term Assets?
Other Long-Term Assets
132m
INR
Based on the financial report for Dec 31, 2025, Metropolis Healthcare Ltd's Other Long-Term Assets amounts to 132m INR.
What is Metropolis Healthcare Ltd's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 5Y
-12%
Over the last year, the Other Long-Term Assets growth was 52%. The average annual Other Long-Term Assets growth rates for Metropolis Healthcare Ltd have been 32% over the past three years , -12% over the past five years .